Insider Transactions Reported by 19 Insiders of Skye Bioscience, Inc.

Symbol: SKYE on Nasdaq
Location: San Diego, CA

Quick Takeaways

SKYE - Skye Bioscience, Inc. has 19 insiders with reported activity on this page.
Net insider value flow over the last year: -$1,601,097.
Recent transaction rows are available for direct filing-level review.

What Changed

Buy value: ; sell value: $1,601,097.
Net share flow: -462,810.

Why This Matters

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Source Evidence

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Net insider flow leans to selling over the last 12 months. Net value: -$1,601,097.

Buys

Shares: 0

Insiders: 0

Sells

$1,601,097

Shares: 462,810

Insiders: 2

Net

-$1,601,097

Shares: -462,810

Insiders: -2

Window (months)	Sell shares	Buy $	Sell $	Net $
0-3	0	$0	$0	$0
3-6	0	$0	$0	$0
6-9	462,810	$0	$1,601,097	-$1,601,097
9-12	0	$0	$0	$0

Skye Bioscience, Inc. executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
Andrew J. Schwab	Director	$34,663,397	-$800,549	-2.3%	Mixed	31 Mar 2026
5AM Partners VII, LLC	10%+ Owner	$34,663,397	-$800,549	-2.3%	Mixed	21 Aug 2025
Versant Ventures III, LLC	10%+ Owner	$9,386,012			Mixed	18 Aug 2023
Emerald Health Sciences Inc.	10%+ Owner	$3,167,928			Mixed	10 Nov 2022
Kaitlyn Arsenault	Chief Financial Officer	$835,935			Filing P/S	06 Feb 2026
Christopher Twitty	Chief Scientific Officer	$147,251			Mixed	31 Mar 2026
Tuan Tu Diep	Chief Operating Officer	$2,880			Mixed	31 Mar 2026
Margaret Dalesandro	Director				Mixed	29 Feb 2024
Praveen Tyle	Director				Mixed	29 Feb 2024
Paul A. Grayson	Director				Mixed	31 Mar 2026
Keith Wayne Ward	Director				Mixed	29 Feb 2024
Punit S. Dhillon	Chief Executive Officer, Director				Mixed	31 Mar 2026
John P. Sharp	Chief Financial Officer				Mixed	31 Mar 2026
Sukhwinder Singh Rai	Director				Mixed	05 Jan 2023
Annalisa Jenkins	Director				Mixed	31 Mar 2026
Karen L. Smith	Director				Mixed	31 Mar 2026
Puneet S. Arora	Chief Medical Officer				Mixed	06 Feb 2026
James L. Heppell	Director				Mixed	14 Sep 2021
Deborah H. Charych	Director				Mixed	31 Mar 2026

Top shareholders of Skye Bioscience, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Andrew J. Schwab	3/4/5	Director	— mixed-class rows	9,756,763 mixed-class rows	$34,663,397	-$800,549	31 Mar 2026	3/4/5
5AM Partners VII, LLC	3/4/5 13D/G	10%+ Owner · Andrew J. Schwab	34% from 13D/G	9,681,763	$34,663,397	-$800,549	21 Aug 2025	3/4/5 13D/G
Versant Ventures III, LLC	3/4/5	10%+ Owner	— class O/S missing	501,925,802	$9,386,012	—	18 Aug 2023	3/4/5
5AM Venture Management, LLC	13F	Company	29%	9,681,763	$5,950,412	—	31 Mar 2026	13F
Schonfeld Strategic Advisors LLC	13D/G	—	3.6%	1,115,939	$4,441,437	-$1,996,997	30 Jun 2025	13D/G
Emerald Health Sciences Inc.	3/4/5	10%+ Owner	— class O/S missing	169,407,901	$3,167,928	—	10 Nov 2022	3/4/5
SPHERA FUNDS MANAGEMENT LTD.	13D/G 13F	Company	4.8%	1,476,353	$2,952,706	$0	31 Mar 2025	13D/G 13F
Versant Venture Management, LLC	13F	Company	5.9%	2,007,704	$1,233,935	—	31 Mar 2026	13F
BAKER BROS. ADVISORS LP	13F	Company	4.6%	1,575,243	$968,144	—	31 Mar 2026	13F
Kaitlyn Arsenault	3/4/5	Chief Financial Officer	— mixed-class rows	292,522 mixed-class rows	$835,935	—	06 Feb 2026	3/4/5
VANGUARD CAPITAL MANAGEMENT LLC	13F	Company	2.3%	764,457	$470,141	—	31 Mar 2026	13F
BlackRock, Inc.	13F	Company	0.84%	286,131	$175,855	—	31 Mar 2026	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.82%	277,256	$170,447	—	31 Mar 2026	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.76%	258,200	$158,690	—	31 Mar 2026	13F
Christopher Twitty	3/4/5	Chief Scientific Officer	0.24%	81,242	$147,251	—	31 Mar 2026	3/4/5
PLATINUM INVESTMENT MANAGEMENT LTD	13F	Company	0.69%	233,095	$143,260	—	31 Mar 2026	13F
VANGUARD FIDUCIARY TRUST CO	13F	Company	0.31%	104,229	$64,101	—	31 Mar 2026	13F
STATE STREET CORP	13F	Company	0.22%	75,326	$46,295	—	31 Mar 2026	13F
UBS Group AG	13F	Company	0.13%	45,762	$28,143	—	31 Mar 2026	13F
XTX Topco Ltd	13F	Company	0.12%	40,919	$25,149	—	31 Mar 2026	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.08%	25,684	$15,785	—	31 Mar 2026	13F
Engineers Gate Manager LP	13F	Company	0.06%	20,194	$12,411	—	31 Mar 2026	13F
NORTHERN TRUST CORP	13F	Company	0.06%	20,142	$12,379	—	31 Mar 2026	13F
BARCLAYS PLC	13F	Company	0.05%	18,089	$11,117	—	31 Mar 2026	13F
GROUP ONE TRADING LLC	13F	Company	0.02%	7,205	$4,428	—	31 Mar 2026	13F
Tuan Tu Diep	3/4/5	Chief Operating Officer	0.01%	4,000	$2,880	—	31 Mar 2026	3/4/5
Vanguard Global Advisers, LLC	13F	Company	0.01%	4,557	$2,803	—	31 Mar 2026	13F
MORGAN STANLEY	13F	Company	0.01%	2,549	$1,567	—	31 Mar 2026	13F
FEDERATED HERMES, INC.	13F	Company	0%	1,158	$712	—	31 Mar 2026	13F
OSAIC HOLDINGS, INC.	13F	Company	0%	600	$364	—	31 Mar 2026	13F
NATIONAL BANK OF CANADA /FI/	13F	Company	0%	400	$242	—	31 Mar 2026	13F
TD Waterhouse Canada Inc.	13F	Company	0%	79	$51	—	31 Mar 2026	13F
JPMORGAN CHASE & CO	13F	Company	0%	66	$39	—	31 Mar 2026	13F
Zurcher Kantonalbank (Zurich Cantonalbank)	13F	Company	0%	52	$32	—	31 Mar 2026	13F
Federation Des Caisses Desjardins du Quebec	13F	Individual	0%	51	$31	—	31 Mar 2026	13F
Rockefeller Capital Management L.P.	13F	Company	0%	39	$24	—	31 Mar 2026	13F
Optiver Holding B.V.	13F	Company	0%	20	$12	—	31 Mar 2026	13F
CoreCap Advisors, LLC	13F	Company	0%	8	$5	—	31 Mar 2026	13F
Plante Moran Financial Advisors, LLC	13F	Company	0%	3	$2	—	31 Mar 2026	13F
CITIGROUP INC	13F	Company	0%	2	$1	—	31 Mar 2026	13F
IFP Advisors, Inc	13F	Company	0%	2	$1	—	31 Mar 2026	13F
MCGUIRE CAPITAL ADVISORS INC	13F	Company	0%	2	$1	—	31 Mar 2026	13F
HARBOUR INVESTMENTS, INC.	13F	Company	0%	1	$1	—	31 Mar 2026	13F
Leo H. Evart, Inc.	13F	Company	0%	1	$1	—	31 Mar 2026	13F
Newbridge Financial Services Group, Inc.	13F	Company	0%	1	$1	—	31 Mar 2026	13F
PFS Partners, LLC	13F	Company	0%	1	$1	—	31 Mar 2026	13F
James L. Heppell	3/4/5	Director	— class O/S missing	1,350,000	—	—	14 Sep 2021	3/4/5
Sukhwinder Singh Rai	3/4/5	Director	— class O/S missing	250,000	—	—	05 Jan 2023	3/4/5
Puneet S. Arora	3/4/5	Chief Medical Officer	— class O/S missing	125,000	—	—	06 Feb 2026	3/4/5
Annalisa Jenkins	3/4/5	Director	— class O/S missing	75,000	—	—	31 Mar 2026	3/4/5

Recent Insider Transactions by Companies or Individuals for Skye Bioscience, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
Karen L. Smith	SKYE	Stock Option (Right to Buy)	Award				75,000	75,000	31 Mar 2026	Direct
Christopher Twitty	SKYE	Stock Option (Right to Buy)	Disposed to Issuer	-100%			-461,104	0	31 Mar 2026	Direct
Christopher Twitty	SKYE	Stock Option (Right to Buy)	Award				461,104	200,000	31 Mar 2026	Direct
Annalisa Jenkins	SKYE	Stock Option (Right to Buy)	Award				75,000	75,000	31 Mar 2026	Direct
Deborah H. Charych	SKYE	Stock Option (Right to Buy)	Award				75,000	75,000	31 Mar 2026	Direct
Paul A. Grayson	SKYE	Stock Option (Right to Buy)	Award				75,000	75,000	31 Mar 2026	Direct
Andrew J. Schwab	SKYE	Stock Option (Right to Buy)	Award				75,000	75,000	31 Mar 2026	Direct
Tuan Tu Diep	SKYE	Stock Option (Right to Buy)	Disposed to Issuer	-100%			-396,295	0	31 Mar 2026	Direct
Tuan Tu Diep	SKYE	Stock Option (Right to Buy)	Award				396,295	150,000	31 Mar 2026	Direct
Punit S. Dhillon	SKYE	Stock Option (Right to Buy)	Disposed to Issuer	-100%			-1,103,959	0	31 Mar 2026	Direct
Punit S. Dhillon	SKYE	Stock Option (Right to Buy)	Award				1,103,959	650,000	31 Mar 2026	Direct
Andrew J. Schwab	SKYE	Stock Option (Right to Buy)	Award				35,000	35,000	06 Feb 2026	Direct
Paul A. Grayson	SKYE	Stock Option (Right to Buy)	Award				35,000	35,000	06 Feb 2026	Direct
Karen L. Smith	SKYE	Stock Option (Right to Buy)	Award				35,000	35,000	06 Feb 2026	Direct
Kaitlyn Arsenault	SKYE	Stock Option (Right to Buy)	Award				125,000	125,000	06 Feb 2026	Direct
Christopher Twitty	SKYE	Stock Option (Right to Buy)	Award				150,000	150,000	06 Feb 2026	Direct
Deborah H. Charych	SKYE	Stock Option (Right to Buy)	Award				35,000	35,000	06 Feb 2026	Direct
Annalisa Jenkins	SKYE	Stock Option (Right to Buy)	Award				35,000	35,000	06 Feb 2026	Direct
Tuan Tu Diep	SKYE	Stock Option (Right to Buy)	Award				125,000	125,000	06 Feb 2026	Direct
Puneet S. Arora	SKYE	Stock Option (Right to Buy)	Award				125,000	125,000	06 Feb 2026	Direct
Punit Dhillon	SKYE	Stock Option (Right to Buy)	Award				280,000	280,000	06 Feb 2026	Direct
Andrew J. Schwab	SKYE	Common Stock	Sale	-10.1%	$22,127	$3.42	-6,470	57,493	22 Aug 2025	By 5AM Co-Investors II, L.P.
Andrew J. Schwab	SKYE	Common Stock	Sale	-10.1%	$560,808	$3.42	-163,979	1,457,064	22 Aug 2025	By 5AM Ventures II, L.P.
5AM Partners VII, LLC	SKYE	Common Stock	Sale	-10.1%	$22,127	$3.42	-6,470	57,493	22 Aug 2025	By 5AM Co-Investors II, L.P.
5AM Partners VII, LLC	SKYE	Common Stock	Sale	-10.1%	$560,808	$3.42	-163,979	1,457,064	22 Aug 2025	By 5AM Ventures II, L.P.
Andrew J. Schwab	SKYE	Common Stock	Sale	-3.49%	$8,261	$3.57	-2,314	63,963	21 Aug 2025	By 5AM Co-Investors II, L.P.
Andrew J. Schwab	SKYE	Common Stock	Sale	-3.49%	$209,352	$3.57	-58,642	1,621,043	21 Aug 2025	By 5AM Ventures II, L.P.
5AM Partners VII, LLC	SKYE	Common Stock	Sale	-3.49%	$8,261	$3.57	-2,314	63,963	21 Aug 2025	By 5AM Co-Investors II, L.P.
5AM Partners VII, LLC	SKYE	Common Stock	Sale	-3.49%	$209,352	$3.57	-58,642	1,621,043	21 Aug 2025	By 5AM Ventures II, L.P.

* An asterisk sign (*) next to the price indicates that the price is likely invalid.